B. Riley Securities Maintains Buy on Perspective Therapeutics, Lowers Price Target to $11
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
B. Riley Securities analyst Yuan Zhi maintains Perspective Therapeutics (AMEX:CATX) with a Buy and lowers the price target from $12 to $11.
B. Riley Securities analyst Yuan Zhi maintains Perspective Therapeutics (AMEX:CATX) with a Buy and lowers the price target from $12 to $11.